Skip to Main Content
Menu Button
About Us
Our Team
Careers
Technology
Clinical Pipeline
News
Contact
2019
Brand Icon
2019,GLP-PK and toxicology studies in rats and dogs were completed and reported by Charles River Laboratories, a renowned US preclinical CRO company,
demonstrating
that QQ-SON was well tolerated with no adverse reactions.
Recent important news
Mar. 2026
Qurgen is happy to announce that the blood and biopsy tissue results of a late-stage of ocular melanoma...
Learn More
Jan. 13, 2026
Dr. Chai Yan Joins Qurgen/Fuent as Senior Vice President for BP，Qurgen, CEO，Suzhou Fuent Pharmaceutics and...
Learn More
